Clinical relevance of IDH1/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group.

Haematologica
Yann FerretAline Renneville

Abstract

Assessment of minimal residual disease has emerged as a powerful prognostic factor in acute myeloid leukemia. In this study, we investigated the potential of IDH1/2 mutations as targets for minimal residual disease assessment in acute myeloid leukemia, since these mutations collectively occur in 15-20% of cases of acute myeloid leukemia and now represent druggable targets. We employed droplet digital polymerase chain reaction assays to quantify IDH1R132, IDH2R140, and IDH2R172 mutations on genomic DNA in 322 samples from 103 adult patients with primary IDH1/2 mutant acute myeloid leukemia and enrolled on Acute Leukemia French Association (ALFA) - 0701 or -0702 clinical trials. The median IDH1/2 mutant allele fraction in bone marrow samples was 42.3% (range, 8.2 - 49.9%) at diagnosis of acute myeloid leukemia, and below the detection limit of 0.2% (range, <0.2 - 39.3%) in complete remission after induction therapy. In univariate analysis, the presence of a normal karyotype, a NPM1 mutation, and an IDH1/2 mutant allele fraction <0.2% in bone marrow after induction therapy were statistically significant predictors of longer disease-free survival. In multivariate analysis, these three variables remained significantly predictive of ...Continue Reading

Citations

Jan 12, 2020·Metabolomics : Official Journal of the Metabolomic Society·Caroline Lo PrestiPascal Mossuz
Dec 7, 2019·Hematology·Sylvie D Freeman, Christopher S Hourigan
Aug 28, 2019·Cells·Isabel CastroPaula Ludovico
Aug 10, 2019·Frontiers in Oncology·Maria Teresa VosoFrancesco Buccisano
Aug 17, 2018·Neurosurgery·Yen-Ying ChenDonald Ming-Tak Ho
Dec 10, 2019·Annals of Hematology·Sabine Khalife-HachemJean-Baptiste Micol
Dec 30, 2020·Leukemia & Lymphoma·Diego CarbonellCarolina Martínez-Laperche
Feb 13, 2021·Frontiers in Oncology·Lok Lam NgaiJacqueline Cloos
Aug 12, 2021·Leukemia·Luca Vincenzo CappelliAlexander Höllein

❮ Previous
Next ❯

Methods Mentioned

BETA
flow cytometry
PCR

Clinical Trials Mentioned

NCT00927498
NCT00932412

Software Mentioned

QuantaSoft
STATA

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.